National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

  • Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel (Duodopa®) - June 14, 2019

    The NCPE recommends that levodopa and carbidopa intestinal gel (Duodopa®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Stiripentol (Diacomit®) - May 3, 2019

    The NCPE recommends that stiripentol (Diacomit®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Cerliponase alfa (Brineura®) - March 26, 2019

    The NCPE recommends that cerliponase alfa (Brineura®) not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Annual NCPE Course - March 25, 2019

    Update on Pharmacoeconomics in the Irish Healthcare Setting, 15th & 16th May 2019 in Dublin Castle. Online access to slides please click here.

  • Pembrolizumab (Keytruda ®) for Urothelial Carcinoma 2L - March 25, 2019

    The NCPE recommends that pembrolizumab (Keytruda®) be considered for reimbursement for this indication if cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Daratumumab (Darzalex®) in combination with bortezomib and dexamethasone - March 15, 2019

    The NCPE recommends that daratumumab combination (Darzalex®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Liraglutide (Victoza®) - March 7, 2019

    The NCPE recommends that liraglutide (Victoza®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

  • Patiromer (Veltassa®) - February 13, 2019

    The NCPE recommends that patiromer (Veltassa®) not be considered for reimbursement.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. 

  • Pertuzumab (Perjeta®) for Adjuvant HER2 positive breast cancer - January 31, 2019

    The NCPE recommends that pertuzumab (in combination with trastuzumab and chemotherapy) for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence (defined here as patients with node-positive or hormone receptor-negative disease), not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.

  • Alectinib (Alecensa®) - January 15, 2019

    Following assessment of the applicant’s submission the NCPE recommends that alectinib (Alecensa®), for the first line treatment of adult patients with ALK-positive advanced NSCLC, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013